AbbVie Inc

ABBV.US
Healthcare · Drug Manufacturers - General
263.20
+6.29 (+2.45%)
USD · NYSE

Company Information

Company Name
AbbVie Inc
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US00287Y1091
CIK: 0001551152
CUSIP: 00287Y109
Currency: USD
Full Time Employees: 57,000
Phone: 847 932 7900
Fiscal Year End: December
IPO Date: Jan 02, 2013
Description:

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Address:

1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

People

Directors & Officers

Name Title Year Born
Mr. Robert A. Michael CPA CEO & Chairman of the Board 1970
Mr. Scott T. Reents Executive VP & CFO 1968
Dr. Azita Saleki-Gerhardt Ph.D. Executive VP & COO 1963
Dr. Roopal B. Thakkar M.D. Executive VP of Research & Development and Chief Scientific Officer 1972
Mr. Jeffrey Ryan Stewart Executive VP & Chief Commercial Officer 1969
Ms. Linda Ray Senior VP & Chief Information Officer NA
Ms. Elizabeth Shea Senior Vice President of Investor Relations NA
Mr. Perry C. Siatis Executive VP, General Counsel & Secretary 1975
Mr. Demetris D. Crum Executive VP & Chief Human Resources Officer 1981
Mr. Wulff-Erik von Borcke Senior VP & President of Oncology NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 30, 2026 Ro Khanna N/A Sale N/A $213.12 N/A
Mar 04, 2026 David Ryan Purdue N/A Sale 5.23K $233.56 $1.22M
Feb 25, 2026 Perry C Siatis N/A Sale 22.38K $230.00 $5.15M
Feb 05, 2026 Ro Khanna N/A Purchase N/A $218.44 N/A
Jan 29, 2026 Ro Khanna N/A Sale N/A $220.42 N/A
Jan 23, 2026 Ro Khanna N/A Purchase N/A $219.21 N/A
Dec 18, 2025 Julie Johnson N/A Sale N/A $222.87 N/A
Dec 08, 2025 Julia Letlow N/A Sale N/A $222.92 N/A
Nov 13, 2025 Julie Johnson N/A Sale N/A $232.25 N/A
Oct 31, 2025 Lisa C. McClain N/A Sale N/A $218.14 N/A
Oct 30, 2025 Lisa C. McClain N/A Sale N/A $228.35 N/A
Oct 30, 2025 Lisa C. McClain N/A Purchase N/A $228.35 N/A
Aug 22, 2025 John Boozman N/A Sale N/A $210.28 N/A
Aug 14, 2025 Julie Johnson N/A Sale N/A $204.78 N/A
Aug 12, 2025 Azita Saleki-Gerhardt N/A Sale 42.37K $198.42 $8.41M
Aug 11, 2025 John Boozman N/A Sale N/A $198.46 N/A
Aug 05, 2025 Nicholas Donoghoe N/A Sale 13.30K $198.51 $2.64M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 180.78M Dec 31, 2025 10.23% $0.60 1.71%
BlackRock Inc 150.70M Mar 31, 2026 8.53% $0.57 -0.32%
Vanguard Capital Management, LLC 114.88M Mar 31, 2026 6.50% $0.62 0.00%
State Street Corp 81.22M Mar 31, 2026 4.60% $0.61 0.34%
JPMorgan Chase & Co 56.74M Mar 31, 2026 3.21% $0.78 8.30%
Vanguard Portfolio Management, LLC 49.52M Mar 31, 2026 2.80% $0.56 0.00%
Geode Capital Management, LLC 46.74M Mar 31, 2026 2.65% $0.63 4.72%
Morgan Stanley - Brokerage Accounts 38.02M Mar 31, 2026 2.15% $0.50 -5.06%
Capital Research Global Investors 31.25M Mar 31, 2026 1.77% $1.05 23.01%
NORGES BANK 25.67M Dec 31, 2025 1.45% $0.63 11.11%
Bank of America Corp 23.94M Mar 31, 2026 1.35% $0.38 -7.31%
FMR Inc 21.76M Mar 31, 2026 1.23% $0.25 -3.74%
Northern Trust Corp 21.21M Mar 31, 2026 1.20% $0.61 -2.40%
Capital World Investors 15.84M Mar 31, 2026 0.90% $0.47 21.19%
The Goldman Sachs Group Inc 15.15M Mar 31, 2026 0.86% $0.38 16.54%
Franklin Resources Inc 14.55M Mar 31, 2026 0.82% $0.78 -2.21%
Capital Research & Mgmt Co - Division 3 14.42M Mar 31, 2026 0.82% $0.74 23.32%
UBS Asset Mgmt Americas Inc 14.16M Mar 31, 2026 0.80% $0.64 9.57%
UBS Group AG 14.05M Mar 31, 2026 0.80% $0.46 33.48%
Bank of New York Mellon Corp 13.28M Mar 31, 2026 0.75% $0.53 -1.64%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 56.10M 3.18% ▼ 0.32% Jun 30, 2026
2 Vanguard 500 Index Investor 45.89M 2.60% ▼ 0.81% Jun 30, 2026
3 iShares Core S&P 500 ETF 24.38M 1.38% ▲ 0.32% Jun 30, 2026
4 Fidelity 500 Index 22.62M 1.28% ▼ 0.14% May 31, 2026
5 State Street® SPDR® S&P 500® ETF 21.36M 1.21% ▼ 1.22% Jun 30, 2026
6 Vanguard Value Index Inv 16.80M 0.95% ▲ 1.83% Jun 30, 2026
7 State Street®HlthCrSelSectSPDR®ETF 12.53M 0.71% ▲ 0.79% Jun 30, 2026
8 Capital Group American Mutual Comp 11.15M 0.63% ▲ 1.57% Jun 30, 2026
9 American Funds American Mutual A 11.15M 0.63% ▲ 1.57% Jun 30, 2026
10 Vanguard Dividend Appreciation ETF 9.98M 0.56% ▲ 0.52% Jun 30, 2026

Financial Highlights

Market Cap: $453.91B
EBITDA: $29.92B
P/E Ratio: $126.56
PEG Ratio: $0.43
Book Value: $-3.77
Dividend/Share: $6.74
Dividend Yield: 2.60%
Earnings/Share: $2.03
Profit Margin: 5.79%
Operating Margin: 32.16%
ROA (TTM): 10.03%
ROE (TTM): 62.25%
Revenue (TTM): $62.82B
Revenue/Share (TTM): $35.50
Earnings Growth (YOY): -46.20%
Revenue Growth (YOY): 12.40%

Valuation Metrics

Enterprise Value: $521.70B
Trailing P/E: 126.56
Forward P/E: 18.38

Shares Statistics

Shares Outstanding: 1.77B
Shares Float: 1.76B
% Insiders: 10.70%
% Institutions: 7,689.90%
Short % Float: 1.42%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$61.16B
Cost of Goods Sold
adjust
$-18.20B
Gross Profit
subtotal
$42.96B
SG&A
adjust
$-14.01B
R&D
adjust
$-9.10B
Operating Income
subtotal
$20.09B
Other / Non-Operating Items
adjust
$-15.87B
Net Income
subtotal
$4.23B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABBV.US!